Le Lézard
Classified in: Health
Subjects: AWD, WOM, SCZ

Brookdale Leadership Named to 2019 Most Influential Corporate Directors List by WomenInc. Magazine


BRENTWOOD, Tenn., Dec. 11, 2019 /PRNewswire/ -- Three members of Brookdale Senior Living's Board of Directors and one former director are named to WomenInc. Magazine's 2019 Most Influential Corporate Directors list. Brookdale's President, CEO and Director Lucinda M. Baier, along with current board members Rita Johnson-Mills and Denise W. Warren and former director the Honorable Jackie M. Clegg, are recognized in the upcoming winter 2019 edition of the magazine.

Lucinda M. Baier, Rita Johnson-Mills, the Honorable Jackie M. Clegg, Denise W. Warren

"We are pleased to receive this recognition as evidence of Brookdale's commitment to diversity," said Baier. "Having a diverse boardroom creates a more collaborative working environment and it speaks volumes to employees and customers. It shows them our leadership is reflective of who they are." Over half of Brookdale's residents are women, about three-quarters of its associates are women and, according to a report in the November 2014 Journal of Health Care for the Poor and Underserved, well over three-quarters of healthcare decisions are made by women.

Brookdale is one of the rare companies nationally to have gender parity among its board members, with four women and four men. Brookdale's stockholders elected Victoria L. Freed to the board in October 2019, as Clegg retired from her seat.

As a leading business magazine reporting on women's success and achievement, the WomenInc.'s Most Influential Corporate Directors issue is a comprehensive listing of women executives, influencers and achievers contributing leadership to corporate boards. WomenInc.'s winter issue is available nationwide as of December 20, 2019.

About Brookdale Senior Living
Brookdale Senior Living Inc. is the leading operator of senior living communities throughout the United States. The Company is committed to providing senior living solutions primarily within properties that are designed, purpose-built, and operated to provide the highest-quality service, care, and living accommodations for residents. Brookdale operates and manages independent living, assisted living, memory care, and continuing care retirement communities, with 794 communities in 45 states and the ability to serve approximately 75,000 residents as of September 30, 2019. The Company also offers a range of home health, hospice, and outpatient therapy services to over 20,000 patients as of that date. Sign up for news alerts at brookdalenews.com.

Contact: Media Relations, 615-564-8666 or [email protected]

SOURCE Brookdale Senior Living


These press releases may also interest you

at 07:10
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended...

at 07:10
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...

at 07:05
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the...

at 07:05
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...

at 07:05
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. today announced an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company...



News published on and distributed by: